AU2023212216A1 - Anti-cd73 antibody and use thereof - Google Patents

Anti-cd73 antibody and use thereof Download PDF

Info

Publication number
AU2023212216A1
AU2023212216A1 AU2023212216A AU2023212216A AU2023212216A1 AU 2023212216 A1 AU2023212216 A1 AU 2023212216A1 AU 2023212216 A AU2023212216 A AU 2023212216A AU 2023212216 A AU2023212216 A AU 2023212216A AU 2023212216 A1 AU2023212216 A1 AU 2023212216A1
Authority
AU
Australia
Prior art keywords
seq
set forth
sequence
sequence set
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023212216A
Other languages
English (en)
Inventor
Mo DAN
Huandi DING
Qingjuan GUO
Xiwu HUI
Ziyi JIN
Wenbin Li
Chao Wang
Bing Yao
Can YUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Megalith Biopharmaceutical Co Ltd
Original Assignee
CSPC Megalith Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Megalith Biopharmaceutical Co Ltd filed Critical CSPC Megalith Biopharmaceutical Co Ltd
Publication of AU2023212216A1 publication Critical patent/AU2023212216A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2023212216A 2022-01-25 2023-01-17 Anti-cd73 antibody and use thereof Pending AU2023212216A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210098976 2022-01-25
CN202210098976.1 2022-01-25
PCT/CN2023/072527 WO2023143227A1 (zh) 2022-01-25 2023-01-17 抗cd73抗体及应用

Publications (1)

Publication Number Publication Date
AU2023212216A1 true AU2023212216A1 (en) 2024-08-08

Family

ID=87470540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023212216A Pending AU2023212216A1 (en) 2022-01-25 2023-01-17 Anti-cd73 antibody and use thereof

Country Status (6)

Country Link
EP (1) EP4471062A4 (https=)
JP (1) JP2025504496A (https=)
KR (1) KR20240139053A (https=)
CN (1) CN118591559A (https=)
AU (1) AU2023212216A1 (https=)
WO (1) WO2023143227A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119744177A (zh) * 2023-07-24 2025-04-01 石药集团巨石生物制药有限公司 重组人源化抗cd73单克隆抗体的药物组合物
WO2025125545A1 (en) * 2023-12-15 2025-06-19 Sanofi Effectorless igg1 fc variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3218406T4 (da) 2014-11-10 2024-12-09 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
MY189836A (en) * 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
KR20230038311A (ko) * 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP3383916B1 (en) 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody

Also Published As

Publication number Publication date
CN118591559A (zh) 2024-09-03
WO2023143227A1 (zh) 2023-08-03
JP2025504496A (ja) 2025-02-12
KR20240139053A (ko) 2024-09-20
EP4471062A1 (en) 2024-12-04
EP4471062A4 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
US20160194402A1 (en) Cd70-binding peptides and method, process and use relating thereto
KR102782109B1 (ko) 신규 항-cd19 항체
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
US11248049B2 (en) Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
AU2023212216A1 (en) Anti-cd73 antibody and use thereof
WO2023104066A1 (zh) 抗cd24抗体及其用途
JP7653532B2 (ja) 抗Ｓｉｇｌｅｃ１５抗体およびその使用
US20240115721A1 (en) Anti-dll3 antibody-drug conjugate
JP7812988B2 (ja) Ｌｅｗｉｓ Ｙに対するヒト化抗体
JP2021501583A (ja) 抗体および使用方法
JP2025541340A (ja) Ｃｕｂ ｄｏｍａｉｎ－ｃｏｎｔａｉｎｉｎｇ ｐｒｏｔｅｉｎ １（ｃｄｃｐ１）に対する抗体およびその使用
EP4725968A1 (en) Anti-gpc3 antibody or antigen-binding fragment and use thereof
CA3222478A1 (en) Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
RU2791445C2 (ru) Новые анти-cd19-антитела
KR20250116579A (ko) Gpc3에 특이적으로 결합하는 신규 항체 및 이의 용도
HK40113267A (zh) 抗磷脂酰肌醇蛋白聚糖3抗体
KR20170076334A (ko) 항 Ang2 항체를 포함하는 혈당 강하제
KR20170076332A (ko) 항 Ang2 항체를 포함하는 면역강화제
CN118324916A (zh) 一种抗人gprc5d的单克隆抗体及其制备方法和用途
EA052951B1 (ru) Биспецифичные антитела против b7-h4/4-1bb и их применение
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom